K. Menard

发表

Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development.

G. Trainor, A. Mathur, D. Langley, 2009, Journal of medicinal chemistry.

Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.

G. Trainor, M. Gottardis, A. Greer, 2010, Bioorganic & medicinal chemistry letters.

Tissue distribution and tumor uptake of folate receptor–targeted epothilone folate conjugate, BMS-753493, in CD2F1 mice after systemic administration

W. Humphreys, F. Lee, J. Gan, 2016, Acta pharmaceutica Sinica. B.

Biochemical and transcriptional profiling to triage additional activities in a series of IGF-1R/IR inhibitors.

P. Ross-Macdonald, H. de Silva, Isaac Neuhaus, 2012, Bioorganic & Medicinal Chemistry.

Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties

M. D. Hill, Derek J. Norris, J. Tokarski, 2022, ACS Medicinal Chemistry Letters.

Development of BET inhibitors as potential treatments for cancer: A search for structural diversity.

M. D. Hill, J. Tokarski, S. Sheriff, 2021, Bioorganic & medicinal chemistry letters.

Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug Design.

Vijay T. Ahuja, Derek J. Norris, J. Tokarski, 2021, Journal of medicinal chemistry.

Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts.

F. Lee, D. Kan, W. Rose, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR

Zheng Yang, G. Trainor, F. Lee, 2009, Molecular Cancer Therapeutics.

BMS-871: a novel orally active pan-Notch inhibitor as an anticancer agent.

Derek J. Norris, D. Shen, G. Trainor, 2015, Bioorganic & medicinal chemistry letters.

Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy

Robert T. Jones, J. Costello, N. Agarwal, 2019, Science Advances.

Preclinical efficacy spectrum and pharmacokinetics of ixabepilone

F. Lee, C. Fairchild, R. Kramer, 2008, Cancer Chemotherapy and Pharmacology.

Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid Tumors.

Derek J. Norris, D. Shen, G. Trainor, 2015, ACS medicinal chemistry letters.